HMGB1, RAGE
(Unterschied zwischen Versionen)
| Zeile 2: | Zeile 2: | ||
{{tp|p=23607598|t=2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome |pdf=|usr=}} | {{tp|p=23607598|t=2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome |pdf=|usr=}} | ||
{{tp|p=32380958|t=2020. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?|pdf=|usr=}} | {{tp|p=32380958|t=2020. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?|pdf=|usr=}} | ||
| + | {{tp|p=32531537|t=2020. RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?|pdf=|usr=009}} | ||
Version vom 7. Juli 2020, 15:11 Uhr
32375153 2020. HMGB1: A Possible Crucial Therapeutic Target for COVID-19?
23607598 2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome
32380958 2020. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?
32531537 2020. RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?
